Liver Pathway Could Target High LDL Cholesterol
Adults with high LDL may one day benefit, as early mouse and lab findings point to a new liver-based treatment target.
Updated on Nov. 2, 2026 in Nutrition
Researchers at the University of California San Diego School of Medicine, with collaborators at UCSF, UT Health San Antonio and the University of Utah, identified a liver pathway that may explain how dietary cholesterol weakens the clearance of LDL, the so-called bad cholesterol. The findings, published in Nature, point to a possible new target for adults with high cholesterol and for heart disease prevention worldwide.
Why it matters
High LDL cholesterol is a major driver of cardiovascular disease, which the WHO recorded as causing 19.8 million deaths worldwide in 2022. Understanding why dietary cholesterol impairs the liver's ability to remove LDL could open new approaches to prevention and treatment beyond diet and existing medications.
The findings come largely from mouse experiments and laboratory studies on human liver cells, supplemented by analysis of human genetic data linking pathway-related gene variations to differences in blood cholesterol. The mouse work tested a CTSA inhibitor after eight weeks of a high-cholesterol diet, and the human data are associational rather than interventional.
The players
University of California San Diego School of Medicine
A leading US medical school whose researchers conduct extensive work in cardiovascular and metabolic disease.
World Health Organization
The UN agency that tracks global cardiovascular disease mortality and sets international health guidance.
Centers for Disease Control and Prevention
The US federal agency that monitors national cholesterol prevalence and chronic disease trends.
The details
Prolonged exposure to dietary cholesterol activates Ral GTPases, proteins that direct LDL receptors into liver cells to be broken down. The enzyme cathepsin A (CTSA) helps degrade these receptors, and in laboratory studies a small-molecule CTSA inhibitor stabilized them, allowing the liver to clear more LDL from the blood. An experimental CTSA-blocking drug has already completed a Phase 1 safety trial for possible heart-failure treatment, though it has not been tested for LDL lowering in people.
Timeline
August 2021 to August 2023: CDC data period showing high total cholesterol in 11.3% of US adults.
2022: WHO recorded 19.8 million cardiovascular deaths worldwide.
- 2026-11-02
Article published on medindia.net.
Health Landscape
Statins work largely by increasing the number of LDL receptors in the liver, so the new finding points to a complementary receptor-protection strategy rather than a replacement. If confirmed in humans, targeting receptor breakdown could add a route for people whose LDL remains high despite current treatment.
For now this is early research, so no change to current cholesterol care follows from it. Adults with high LDL should keep discussing their numbers and treatment options with their physician, who can judge their individual risk.
The takeaway
Diet can affect how well the liver clears LDL, and this pathway may eventually become a target for new cholesterol therapies. Keeping an eye on updated guidance and asking your doctor about your lipid panel remain the practical steps today.
What happens next
A Phase 2 trial must assess the experimental CTSA-blocking drug's effectiveness and risks before any human LDL-lowering use is considered.
Further reading
For more on how what we eat shapes cholesterol, explore our Nutrition coverage.
Source note: This article includes information reported by Medindia.
